U.S. markets open in 21 minutes
  • S&P Futures

    3,852.25
    +43.00 (+1.13%)
     
  • Dow Futures

    31,262.00
    +350.00 (+1.13%)
     
  • Nasdaq Futures

    13,073.00
    +162.00 (+1.25%)
     
  • Russell 2000 Futures

    2,240.40
    +41.20 (+1.87%)
     
  • Crude Oil

    61.71
    +0.21 (+0.34%)
     
  • Gold

    1,734.10
    +5.30 (+0.31%)
     
  • Silver

    26.95
    +0.51 (+1.95%)
     
  • EUR/USD

    1.2051
    -0.0036 (-0.30%)
     
  • 10-Yr Bond

    1.4320
    -0.0280 (-1.92%)
     
  • Vix

    24.72
    -4.17 (-14.43%)
     
  • GBP/USD

    1.3939
    +0.0016 (+0.12%)
     
  • USD/JPY

    106.6530
    +0.1510 (+0.14%)
     
  • BTC-USD

    47,907.66
    +3,249.04 (+7.28%)
     
  • CMC Crypto 200

    961.96
    +28.83 (+3.09%)
     
  • FTSE 100

    6,559.37
    +75.94 (+1.17%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

ImmunoGen Announces Conference Call to Discuss Its 2020 Operating Results

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 12, 2021 to discuss its 2020 operating results. Management will also provide a brief update on the business.

Conference Call Information

To access the live call by phone, dial (877) 621-5803; the conference ID is 1666147. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the webcast, a replay of the call will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210129005034/en/

Contacts

INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com